• Syra Health swung to a GAAP profit in Q2 2026, posting net income of USD 250,242 versus a loss a year earlier; EPS was USD 0.02.
• Revenue rose 23% year over year to USD 2.4 million; gross margin widened 5.8 percentage points to 44.5%.
• GAAP operating income was USD 251,571; GAAP EBITDA turned positive to USD 253,200 from a loss a year earlier.
• Population health solutions revenue increased 8% to USD 1.72 million; healthcare workforce revenue more than doubled to USD 678,113.
• Syra Health reiterated its 2026 target for full-year profitability, citing contract extensions and expected near-term CMS ACCESS Model approval with HealthSync.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syra Health Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608110755PR_NEWS_USPR_____DE22910) on August 11, 2026, and is solely responsible for the information contained therein.